Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive advanced stage non-small-cell lung cancer

Faculty Medicine Year: 2018
Type of Publication: ZU Hosted Pages:
Authors:
Journal: Cancer Management and Research DOVE MEDICAL PRESS LTD Volume:
Keywords : Efficacy , safety , crizotinib , patients with anaplastic    
Abstract:
Lung cancer is the leading cause of cancer mortality worldwide, despite advances in management, especially with targeted agents and immunotherapy. Numerous oncogenes have been identified that control the growth of these malignancies. Anaplastic lymphoma kinas (ALK) is a tyrosine kinase that develops distorted functioning as a result of chromosomal rearrangement. Crizotinib, a tyrosine kinase inhibitor (TKI), was approved by the Food and Drug Administration (FDA) in 2011 for the treatment of advanced ALK-positive non-small-cell lung cancer (NSCLC). -In NSCLC, crizotinib is a viable treatment option with good response and tolerable toxicity for patients with ALK-positive advanced disease
    
     
 
       

Author Related Publications

    Department Related Publications

    • Rasha Mohamed Mostafa Hagag, "Impact of Prognostic Nutritional Index and Systemic Immune-Inflammation Index on the Clinical Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib", Zagazig University Medical Journal, 2022 More
    • Rasha Mohamed Mostafa Hagag, "Diagnosis of Sepsis among Adult Patients with AML Using Scd14", Ain Shams University, Faculty of Medicine, Pan Arab League of Continuous Medical Education, 2021 More
    • Rasha Mohamed Mostafa Hagag, "Prognostic Impact of microRNAs (miR-155, miR-10a, let-7a) on the Outcome of Adult Patients with Acute Myeloid Leukemia.", Zagazig University, Faculty of Medicine, 2021 More
    • Shereen Mostafa Saleh Elshorbagy, "Prognostic Roles of ZNF703 and SMAD4 Expression in Patients with Papillary Thyroid Cancer and Association with Nodal Metastasis", pubmed, 2022 More
    • Shereen Mostafa Saleh Elshorbagy, "RNA-binding proteins RBM-HuR, RBM3 and PODXL expression in urothelial carcinoma of the urinary bladder. Prognostic and clinical implications", PMID: 35079236, 2022 More
    Tweet